

ANI PHARMACEUTICALS INC  
Form 8-K  
February 03, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 29, 2015**

**ANI PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-31812</b> (Commission File Number)	<b>58-2301143</b> (I.R.S. Employer Identification Number)
--	--	---

**210 Main Street West**

**56623**

**Baudette, Minnesota**

Edgar Filing: ANI PHARMACEUTICALS INC - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(218) 634-3500**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
Compensatory Arrangements of Certain Officers.

On January 29, 2015, Robert Jammick, Vice President, Quality and Product Development, retired.

Item 8.01 Other Events.

On February 3, 2015, ANI Pharmaceuticals, Inc. announced the promotion of David J. Sullivan, Ph.D. to the position of Vice President, Quality Operations.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

Exhibit No. **Description**

99.1 Press release of ANI Pharmaceuticals, Inc., dated February 3, 2015

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANI  
PHARMACEUTICALS, INC.**

By: */s/ Charlotte C.  
Arnold  
Charlotte C. Arnold  
Vice President, Finance  
and Chief Financial  
Officer*

Dated: February 3, 2015